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Study design: An experimental study examining the neuroprotective eect of magnesium on
axonal function and lipid peroxidation in a rat model of acute traumatic spinal cord injury.
Objective: To determine the eectiveness of postinjury treatment with magnesium on evoked
potentials and lipid peroxidation after spinal cord injury (SCI).
Setting: Pamukkale University, Denizli, Turkey.
Methods: Spinal cord injury occurred in 30 rats with an aneurysm clip at T9 and the rats
were randomly assigned to undergo subcutaneous administration of one of the following at
1 h after injury: (1) Physiological saline (n=10); (2) MgSO4, 300 mg/kg (n=10) and (3)
MgSO4, 600 mg/kg (n=10). Spinal somatosensory evoked potentials (SSEPs) were recorded
before injury, 30 min after injury and 3 h after injections. Rats were killed 24 h after the
injury, and malondialdehyde (MDA) levels were measured.
Results: Following SCI, there were signi®cant decreases in the amplitudes of P1 and N1
(P50.001) and only high-dose magnesium improved the SSEPs (P50.01). On the other hand,
there was signi®cant dierence in lipid peroxide content between high-dose magnesium treated
group and both of saline treated and low-dose magnesium treated groups (P50.01).
Conclusion: These results suggest that magnesium has a dose-dependent neuroprotective
eect on SSEPs and lipid peroxidation after experimental spinal cord injury.
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Introduction
The pathophysiology of spinal cord injury is complex
and has not been fully elucidated.1 There is evidence
that progressive pathophysiological changes occur at
the level of trauma, resulting in a reduction in spinal
cord blood ¯ow and a decrease in the tissue oxygen
levels and all these lead to ischemia and the subsequent
second injury.2 ± 7 Moreover, release or activation of
autodestructive factors causes to lipid peroxidation and
calcium-mediated cellular toxicity.8,9 It is believed that
these mechanisms are interactive.1,10,11
Much evidence implicates the in¯ux of calcium ions
via the N-methyl-D-aspartate (NMDA) receptor
complex in pathogenesis of ischemic injury and cell
death.12,13 A variety of pharmacological agents
designed to prevent NMDA receptor activation or to
modify the cascade of events that follow this
activation have been synthesized.
Magnesium is a readily available, inexpensive
NMDA receptor antagonist with a well established
clinical pro®le in obstetrical and cardiovascular
practice.14,15 Magnesium ions play an important role
in neuronal cellular physiology by competing with
calcium ions, acting as an endogenous calcium channel
blocker and gating NMDA receptor-associated ion
channels.16 Moreover, magnesium is essential for
normal cell functions such as membrane integrity,
cellular respiration, transcription by messenger RNA,
protein synthesis, glucose and energy metabolism, and
regulation and Ca2+ transport and accumulation.17 ± 20
Feldman et al21 have reported that, postinjury
treatment with Mg2+ attenuated brain edema forma-
tion and improved neurological outcome after experi-
mental head trauma in rats. On the basis of these data,
we conducted the present study to determine the
ecacy of magnesium as a neuroprotective agent in a
rat model of spinal cord injury.
Materials and methods
Surgical procedure
Our experimental protocol was approved by the
Animal Care and Use Committee of Pamukkale
University. Thirty adult male albino rats, weighing
between 210 and 310 g were used for the experiments.
Animals were anesthetized by an intraperitoneal
injection of ketamine (50 mg/kg) and xylazine (9 mg/
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kg). The right femoral artery and vein were cannulated.
Lactated Ringers solution was administered intrave-
nously to maintain hydration. The arterial line was
used to monitor heart rate and blood pressure, and to
assess arterial blood gases. During surgical procedures,
body temperature was maintained between 37 and
388C with a water-®lled heating pad. The spinal cord
was exposed by a bilateral laminectomy of T9. All
animals were subjected to an extradural clip compres-
sion of the cord at T9 with an aneurysm clip (Yasargil,
FE 691K, Aesculap AG, Germany) exerting a force of
50 g for 30 s, an injury which caused paraplegia.
Evoked potentials
It was previously reported that the spinal somatosen-
sory evoked potentials were not in¯uenced by
anesthetic levels of ketamine unlike cortical somato-
sensory evoked potentials, so that we used spinal
somatosensory evoked potentials (SSEPs) to monitor
axonal function.22 The SSEPs were obtained with a
Medelec Premiere Plus (Medelec Ltd., UK) prior to
injury and at 30 min and 4 h after the injury. The
recording electrodes were inserted percutaneously just
lateral to spinous process of the T2, so that the tips
rested on the laminae. To record the SSEPs, left sciatic
nerve was stimulated by bipolar electrodes with square
wave pulses of 0.1 ms duration and 5 mA intensity
delivered at 5 Hz. The ®lter range was 3 Hz to 3 kHz.
Sixty-four responses were averaged and displayed. The
SSEPs recorded before and after the spinal cord injury
were compared by measuring the latency and
amplitude of each component wave.
Experimental protocol
Following the preinjury SSEP recordings, all animals
were subjected to a spinal cord compression injury at
T9 with a 50 g aneurysm clip for 30 s. The SSEPs were
recorded at 30 min after injury. After these recordings,
the rats were randomly assigned to subcutaneous
injection of either (1) physiological saline, (n=10); (2)
MgSO4, 300 mg/kg (n=10) or (3) MgSO4, 600 mg/kg
(n=10). Posttreatment SSEP recordings were obtained
at 3 h after injections. When the animals awakened
from anesthesia after the study, they were returned to
their cages and the bladders were compressed manually
every 6 h.
Estimation of lipid peroxide
All the animals were killed by intracardiac injection of
KCl 24 h after trauma, and the T9 spinal cord segment
was removed quickly (within 30 s) and immediately
frozen with liquid nitrogen. Tissues were homogenised
in ice-cold KCl (1.5% w/v) to make a 10% homogenate
(w/v) using a glass Te¯on homogeniser. Lipid peroxide
was estimated according to the method of Rehncrona et
al.23 Aliquots of spinal cord homogenates were
extracted with 0.5 ml of trichloroacetic acid (20%
w/v). After centrifugation for 10 min at 3000 rpm,
0.9 ml supernatant was added to 1.0 ml of thiobarbi-
turic acid (0.67% w/v) dissolved in 0.26 M Tris-HCl
buer. The samples were heated in boiling water for
10 min. After cooling, the absorbance was recorded at
532 nm. The amounts of lipid peroxides were calculated
as thiobarbituric acid reactive substances (TBARS) and
tetraethoxypropane was used as standard. The content
of TBARS was calculated by comparison with the
standard curve, and the level of lipid peroxides was
expressed as nanomoles per gram of wet tissue.
Statistical analysis
All data were evaluated in a blinded fashion and
expressed as the mean+SD. SPSS statistics package
(SPSS Inc., Chicago, IL, USA) was used for all
statistical processing. Statistical comparisons were
performed using analysis of variance (ANOVA),
Tukey's honestly signi®cant dierence (HSD) test,
paired t-test and Wilcoxon matched-pairs signed-ranks




Representative preinjury, postinjury and posttreatment
SSEP recordings are illustrated in Figure 1. ANOVA
and Tukey's HSD test revealed no signi®cant
dierences in the amplitudes of both P1 and N1
among the three treatment groups before the injury.
The amplitudes of SSEPs were decreased signi®cantly
at 30 min after the injury in all 30 animals (paired t-
test, P50.001). Moreover, Wilcoxon matched-pairs
signed-ranks test revealed signi®cant dierences be-
Figure 1 Representative SSEP recordings before and 30min
after the spinal cord injury, and 3 h after the administration
of MgSO4 (600mg/kg). The amplitudes of SSEPs were
signi®cantly attenuated at 30min after spinal cord injury.
There was signi®cant improvement in the amplitudes of
SSEPs in the high-dose (600mg/kg) magnesium treated
animals
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tween the postinjury and preinjury amplitudes of P1
(P50.01) and N1 (P50.01) for all groups. The
reduction in the N1 and P1 amplitudes did not
recover in the saline treated (P40.05) and low-dose
magnesium treated (P40.05) groups. In the high-dose
magnesium treated groups, there was signi®cant
improvement in the amplitudes of P1 (P50.01) and
N1 (P50.01) when compared with postinjury measure-
ments (Figure 2).
Biochemistry studies
MDA contents in each treatment group were shown in
Figure 3. The dierence between saline treated and
low-dose magnesium treated groups was statistically
insigni®cant (P40.05). The MDA content was found
to be lower in the high-dose magnesium treated group
than in the saline treated and low-dose magnesium
treated groups (P50.01).
Discussion
It has been reported that spinal cord injury is caused
by direct and indirect mechanisms.7,24,25 The patholo-
gical lesion in the spinal cord injury requires 1 ± 2 h to
develop.24,26 This lag time is necessary to allow a
delayed injury process. Secondary injury processes
include ischemia, release of excitotoxic neurotransmit-
ters, free radical generation, lipid peroxidation, and
in¯ux of calcium ions in to the neurons.
Neuroprotective eects of high-dose methylpredin-
solone, opiate receptor antagonists, and calcium
channel antagonists on spinal cord injury have been
reported. Methylprednisolone suppresses the break-
down of membranes by inhibiting lipid peroxidation
and hydrolysis at the site of injury.27 ± 29 Since Faden
et al30 reported that opiate system play a major role in
the pathophysiology of spinal cord injury, opiate
receptor antagonist naloxane has been widely used in
the treatment of spinal cord injury.31 ± 33 Calcium
antagonists have been shown to increase blood ¯ow
in the brain and spinal cord, and decrease cellular
toxicity; thus, they have been extensively studied in
spinal cord trauma.1,7,33,35
Neuroprotective eects of magnesium has been
shown in experimental models of permanent focal
cerebral ischemia, transient global ischemia, spinal
cord ischemia, traumatic brain injury, topically
induced quinolinate hippocampal neurodegeneration,
perinatal postasphyxial brain damage, and delayed
cerebral vasospasm after subarachnoidal haemor-
rhage.12,36 ± 38 Marinov et al12 have shown the
bene®cial eect of magnesium in rats subjected to
transient focal cerebral ischemia, and suggested that
the neuroprotective eect of magnesium was dose
dependent and could be documented by improved
neurological outcome, decreased volume of infarct,
and diminished histological evidence of neuronal
injury in the ischemic border zone. McIntosh et al37
have studied the eect of magnesium after traumatic
brain injury in rats, and postulated that postinjury
treatment with magnesium was eective in limiting the
extent of neurological motor dysfunction. Ram et al38
have shown the bene®cial eect of magnesium sulfate
in the treatment of subarachnoidal haemorrhage-
induced vasospasm in rat. Feria et al39 have reported
Figure 2 Bar graphs showing the amplitudes of P1 (upper)
and N1 (lower) in each experimental group (n=10 per
group). The animals were treated 1 h after spinal cord injury
with saline, 300mg/kg (Mg300) or 600mg/kg (Mg 600)
MgSO4. The amplitudes of P1 and N1 were signi®cantly
recovered in the high-dose Mg treated group when compared
with postinjury measurements (*P50.01)
Figure 3 Bar graphs showing the MDA contents in each
treatment group. MDA content was found to be lower in the
high-dose magnesium treated group when compared with
saline treated and low-dose magnesium treated groups
(*P50.01). The dierence between saline treated and low-
dose magnesium treated groups was statistically insigni®cant
(P50.05)
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an almost complete suppression of autonomy in rats
deaerented by sciatic and saphenous neurectomy
30 min after being injected with magnesium sulfate.
It has been shown that magnesium ions play an
important role in neuronal cellular physiology by
competing with calcium ions, acting as endogenous
calcium channel blocker and gating NMDA receptor-
associated ion channels. Moreover, magnesium is
essential for a number of cellular processes, including
glycolysis, oxidative phosphorylation, protein synthesis
DNA and RNA aggregation, and the maintenance of
plasma membrane integrity. Neuroprotective mechan-
ism of magnesium include inhibition of excitatory
neurotransmitter release, blockage of calcium channels
and blockage of the NMDA-glutamate receptor.
This is the ®rst study correlating the decrease of
lipid peroxidation measured by MDA levels and
improvement of axonal function assessed by SSEP
caused by magnesium treatment in spinal cord injury.
Our study provided quantitative evidence demonstrat-
ing that high-dose (600 mg/kg) magnesium signifi-
cantly attenuates the increase in MDA levels observed
after spinal cord injury. Magnesium treatment used in
this study was also shown to improve axonal function
assessed by evoked potentials. Low-dose (300 mg/kg)
magnesium, however, was not eective.
Hall and Braughler6 reported that cell membrane
damage after spinal cord injury might be induced by
free-radical reaction and lipid peroxidation. Experi-
ments have shown that the free-radical-initiated
peroxidative procedure occurs in the injured spinal
cord.4,6,8,11,24,29,40 In this study, tissue lipid peroxida-
tion was evaluated by measuring the thiobarbituric
acid reactive substances (TBARS).23 MDA, formed
from the breakdown of polyunsaturated fatty acids,
serves as a convenient index for determining the extent
of lipid peroxidation. MDA is also a well known
secondary product of lipid peroxidation in spinal
myelin, glial, and neuronal membranes.24,41 The
results of our study demonstrated that MDA levels
in the high-dose MgSO4 treated group were signifi-
cantly lower than the saline treated group and the low-
dose MgSO4 treated group (Figure 3).
It is known that there is still controversy regarding
the values of evoked potentials for assessing the
electrophysiological integrity of the spinal cord after
SCI. Ross and Tator1 reported that their experiment
failed to demonstrate an improvement in electrophy-
siological function in any rat at any time after SCI.
Nacimiento et al42 concluded that SSEP changes in
cats did not re¯ect the severity of acute SCI. However,
several studies in rats using clip compression injury
have demonstrated bene®cial eects on evoked
potentials after drug treatments.7,35,43 To check the
lesion severity and evoked potential responses, we
performed a preliminary study using the same
aneurysm clip (50 g) for 1 min compression injury,
and we were not able to analyse the amplitudes
because of the large number of absent responses; thus
the compression time was chosen to be 30 s. In our
study, decline in the amplitudes if SSEPs occurred
after clip compression signi®cantly improved in high-
dose magnesium treated group. However, the de-
creased amplitudes did not recover in saline treated
and low-dose magnesium treated groups.
The present study demonstrated that postinjury
treatment with magnesium after traumatic spinal cord
injury attenuated lipid peroxidation and improved
axonal function. One possible mechanism for its
bene®cial eect is the blockage of the calcium
channels and NMDA-glutamate receptor; magnesium
blocks NMDA receptor-ion channel in the brain and
spinal cord.16,21 A second possible mechanism is the
essential role of magnesium for a number of cellular
processes, including regulation of calcium transport,
glycolysis, protein synthesis, and the maintenance of
plasma membrane integrity.17,18,37 In addition, it is
known that a fall in intracellular free and total
magnesium occurs following traumatic injury and
Mg de®ciency exacerbates posttraumatic neurologic
dysfunction; treatment with Mg prevents the fall in
intracellular free magnesium.19,37
Our study did not reveal the underlying mechanisms
by which the improvement by magnesium was brought
out. Further eorts should be made to explore these
mechanisms in more detail and to develop optimum
treatment strategies.
In summary, the results of this study indicate a
signi®cant bene®cial eect of magnesium in rats
subjected to spinal cord injury. The neuroprotection
was dose-dependent and could be documented by
improved electrophysiological function and decreased
lipid peroxidation. Further work is needed to evaluate
the routes, dosages and conditions with which the
administration of magnesium could be valuable for the
neuroprotection in spinal cord injury.
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